Eli Lilly and Company has announced groundbreaking Phase 3 results for its investigational triple agonist, retatrutide, demonstrating significant efficacy in…
Read More

Eli Lilly and Company has announced groundbreaking Phase 3 results for its investigational triple agonist, retatrutide, demonstrating significant efficacy in…
Read More
Eli Lilly has significantly bolstered its position in the competitive metabolic disease landscape with detailed Phase 3 results for its…
Read More
Eli Lilly and Company utilized the prestigious platform of the American Diabetes Association’s (ADA) annual meeting to unveil groundbreaking Phase…
Read More
The Dawn of a New Era in Metabolic Disease Management The announcement at the ADA meeting highlighted retatrutide’s remarkable efficacy,…
Read More
Eli Lilly announced groundbreaking detailed Phase 3 results for its investigational triple agonist, retatrutide, at the American Diabetes Association’s (ADA)…
Read More
Gilead Sciences has announced a significant commitment to global health, pledging over 400,000 doses of its vital antifungal medication, AmBisome…
Read More
In a groundbreaking development that blurs the lines between species and aging research, scientists have successfully transferred a key longevity-associated…
Read More
A groundbreaking, albeit small-scale, clinical trial has offered a glimmer of hope for pregnant individuals battling preeclampsia, a serious and…
Read More
The biopharmaceutical and biotechnology sectors have recently experienced an extraordinary period of accelerated activity, marked by a rapid succession of…
Read More